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A combination of photodynamic therapy and
antimicrobial compounds to treat skin and
mucosal infections: a systematic review†
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Background: Antimicrobial photodynamic therapy (aPDT) is a growing approach to treat skin and mucosal
infections. Despite its effectiveness, investigators have explored whether aPDT can be further combined
with antibiotics and antifungal drugs. Objective: To systematically assess the in vivo studies on the effec-
tiveness of combinations of aPTD plus antimicrobials in the treatment of cutaneous and mucosal infec-
tions. Materials and methods: Searches were performed in four databases (PubMed, EMBASE, Cochrane
library databases, ClinicaTrials.gov) until July 2018. The pooled information was evaluated according to
the PRISMA guidelines. Results: 11 full-text articles were finally evaluated and included. The best aPDT
combinations involved 5-aminolevulinic acid or phenothiazinium dye-based aPDT. In general, the combi-
nation shows benefits such as reducing treatment times, lowering drug dosages, decreasing drug toxicity,
improving patient compliance and diminishing the risk of developing resistance. The mechanism of action
may be that first aPDT damages the microbial cell wall or membrane, which allows better penetration of
the antimicrobial drug. Limitations: The number of studies was low, the protocols used were hetero-
geneous, and there was a lack of clinical trials. Conclusions: The additive or synergistic effect of aPDT
combined with antimicrobials could be promising to manage skin and mucosal infections, helping to
overcome the microbial drug resistance.
Introduction
The problem of microbial drug resistance
After more than half a century of decline, microbial infections
are now increasing again (not decreasing) with a significant
impact on mortality and morbidity rates, as well as the associated
financial burden. This renewed increase is largely caused by the
development of multidrug resistance (MDR).1 Microbial resis-
tance to antibiotics in both community and hospital settings has
been increasing worldwide in the last two decades, and seems
likely to continue to increase further in the near future.2,3
New molecules are being developed to meet the need for
compounds with activity against resistant pathogens.4 In par-
ticular, the Infectious Diseases Society of America has sup-
ported an initiative to develop ten new antibacterial agents by
the year 2020: “10 × 20 Initiative”.5 However, despite these new
antibiotics, the increasing prevalence of antibiotic-resistant
bacterial infections has not been halted.6 To meet this threat,
alternative non-antibiotic therapies are necessary.
Antimicrobial photodynamic therapy (aPDT) has been pro-
posed as one alternative treatment for localized infections,
especially cutaneous or mucosal infections.7,8
Antimicrobial photodynamic therapy: achievements and
challenges
aPDT is based on the use of non-toxic dyes or photosensitizer
molecules (PS) that are activated by harmless visible light in
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the presence of oxygen; this combination is able to generate
reactive oxygen species (ROS) such as superoxide anion, hydro-
gen peroxide or hydroxyl radical (Type I) and/or singlet oxygen
(Type II). All these different ROS can oxidize various biological
molecules, such as proteins, nucleic acids, and lipids, leading
to cell death and destruction of microorganisms.8,9 Fig. 1 of
the ESI† summarizes the process.
One advantage of aPDT for infections is the possibility of
eliminating microorganisms independently of their anti-
microbial resistance pattern, and without requiring a precise
microbial diagnosis. The advantages also include a broad spec-
trum of activity, a very rapid response time (seconds or
minutes), a low probability of adverse side effects, and the
modest cost of treatment.10 Whereas the most important limit-
ations are the possibility of regrowth of those microorgnisms
that were not inactivated during the irradiation, some photo-
toxicity can occur also in some tissues or host cells, pain
during the irradiation with some protocols, and the lack of
standardized clinical protocols.8,11,12
An option that paves the way for the future is the combi-
nation of aPDT treatment with conventional antimicrobials in
order to achieve an additive or synergistic therapeutic effect or
even to overcome antimicrobial resistance.13,14 This original
approach points to potentially new and versatile applications
for the therapy of superficial cutaneous infections. This option
could help widen the use of aPDT, and reduce the amount of
antibiotics used, thereby diminishing the problem of MDR.8,15
Table 1 summarizes the possible advantages. The key issue is
that the addition of antimicrobials to in vivo aPDT might
prevent microbial regrowth when the light is turned off, and
the antimicrobial effects of the photogenerated ROS rapidly
cease. During the preparation of the present review, another
excellent review by Wozniak and Grinholc appeared, which
contained some overlapping material with the present
review.14 Nevertheless, we believe that the two review articles
are complementary in nature rather than duplicative.
Objective
The aim of this review is to determine the utility of the combi-
nations of aPTD plus antimicrobials (aPDT and antimicrobial
simultaneously given, aPDT followed by antimicrobial or vice
versa) to treat skin and mucosal infections in humans or
animals.
The questions that are intended to be answered are: (1)
which skin and mucous infections have been treated with
combinations of aPDT and antimicrobials; (2) which method-
ologies have been used; and (3) what do the results indicate.
Methods
This review was written following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.16,17 The systematic review of the literature was
carried out as detailed below.
Eligibility criteria
We have taken into account in vivo studies that used anti-
microbial treatments plus aPDT against skin and mucosal
infections. The specific requirements for inclusion of the
studies were (1) in vivo studies in humans or animals including
those that used animals as a model; (2) aimed to treat skin
and/or mucosal infections; (3) caused by identified bacteria,
yeast or fungi; (4) used antibiotics or antifungals as a funda-
mental part of the treatment; (5) used aPDT as a fundamental
part of the treatment; (6) published in indexed journals and
written in English or Spanish.
Information sources and search
Pubmed, Embase, Clinicaltrial.gov and Cochrane library data-
bases were used. Two independent reviewers performed the
search and cross-checked their findings. No time limits were
used in the search for articles. The last search was carried out
in July 2018. The keywords used for the search were: photo-
dynamic therapy, PDT, antimicrobial photodynamic therapy,
aPDT, photodynamic antimicrobial chemotherapy, PACT,
photoinactivation, photodynamic inactivation, PDI, combi-
nation, combined treatment, antimicrobials, antibiotics and
antifungals.
Study selection
All studies that meet the selection criteria were included.
Data collection process
The methodology of the antimicrobial treatment and aPDT
were listed in a table. The data recapitulated in clusters were:
(1) causative agent of skin and/or mucosal infection; (2) type of
in vivo study: animal model or patients; (3) antimicrobial
methodology: antibiotics or antifungals used and their appli-
cation and dose; (4) aPDT methodology: PS used, parameters
of irradiation (source type, wavelength and intensity), number
of sessions and fluence and (5) observed effect of combined
treatment on infection.
Risk of bias in individual studies
The risk of bias of individual studies was assessed in each
study and taken into account at the outcome level when the
data synthesis was carried out. We identified domains of bias
such as selection bias, performance bias, detection bias, attri-
Table 1 Most important possible advantages of the combination of
aPDT and classical antimicrobial treatment
1 They are complementary treatments because on using low doses
of both, they obtain better results
aPDT: Antimicrobial:
Less staining of the skin Lower dose
Less photodynamic dose Less side effects
Less number of treatments
2 No selection of resistant microorganisms
3 Less risk of microorganism proliferation and treatment failure
aPDT: antimicrobial photodynamic therapy.
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tion bias, reporting bias and other potential sources of bias
following the recommendations of The Cochrane for the
evaluation.18
Summary measures and the synthesis of results
A table with the collected data was created to facilitate data
handling and the combination of the results of the studies.
Due to the heterogeneity of the studies in terms of method-
ology and treatment protocol, the outcomes were presented in
a descriptive manner. The observed effect of the combined
treatments on infections was collected in any of the ways
reported in each study (difference in proportions between
groups, confidence intervals, clinical follow-up of the lesions
and microbiological diagnosis).
Risk of bias across studies
The risk of bias across studies such as publication bias and




A huge number of papers contained the keywords selected for
our search. Nevertheless after applying the eligibility criteria,
the number was drastically reduced to a total of 11 studies,
which have been assessed and included in this review.
Study characteristics & synthesis of results
The 11 studies that fulfilled the selection criteria were
screened: the group was composed of clinical cases (N = 7, ten
patients) or experiments in animal models using mice (N = 2)
or Galleria mellonella larvae (N = 2). Among them, 2 dealt with
bacterial infections caused by Gram negatives, 2 against atypi-
cal mycobacterial infections, 2 against candidiasis, and 5
against dermatophytoses and other mold infections. All were
assessed and included in the review, grouped depending on
the causal agent of skin and/or mucous infection. Table 2
summarizes the data extracted from the studies reporting com-
binations of in vivo aPDT plus other treatments against bac-
terial infections, candidiasis, atypical Mycobacterium species,
dermatophytoses and mold infections of the skin and mucosa.
Risk of bias within studies
Table 3 summarizes the risk of bias within studies. All clinical
cases involved a high risk of selection, performance and detec-
tion biases because they were not randomized and there was
no blinding. The clinician established the treatment protocol
for the specific patient, the patient agreed with it and therefore
the evaluators of the result (patient and clinical staff ) knew
the applied treatment. There was only one patient treated with
systemic antibiotics for a cutaneous infection caused by
Mycobacterium fortuitum on the hands who received addition-
ally two sessions of ALA-PDT in only one hand which showed a
significant improvement compared with the other hand.24
This is the reason why in this study, the risk of detection bias
was considered unclear instead of high. Attrition bias risk was
considered unclear in all cases, because the loss of patients
was not reported, but it is not known whether other patients
refused the treatment or did not complete it. In the clinical
cases (one patient per study except in that of Sun et al. with
four patients), these are not clinical trials with a significant
number of patients.19 Reporting bias risk also was considered
unclear: the study protocols are available but the possible
results are not prewritten and the results are reported descrip-
tively. Only in the study of Gilaberte et al. was the clinical
improvement confirmed with microbiological analysis32 and
therefore the risk was considered minor.
In the four studies using animal models, a low risk of selec-
tion bias was considered because they used a random method
to establish each group. Namely, until the time of assignment,
the group in which a particular animal would be included was
unknown. However, a high risk of performance bias and in the
reporting of the results was considered because there was no
blinding of personnel either during the experiment or at the
moment of evaluating the outcomes. The personnel knew the
treatment for each group all the time and it cannot be
excluded that this influenced the evaluation of the results. The
validity of the variables with regard to the assessment of the
results of the study was considered to have a low risk of bias in
the two studies of Chibebe et al. and in the study of Baltazar
et al. because all variables were covered by the different groups
of animals.20,21 However, not enough information was avail-
able to make a clear judgment in the study of Lu et al. (e.g., no
group of mice was only exposed to light).22 On the other hand,
the low risk of attrition and reporting biases were considered
in all studies because they did not report the loss of animals
in any group (no incomplete outcome data) and the protocol is
available and all results are described as planned (no selective
outcome reporting) with the exception of the study of Lu et al.
in which unclear reporting bias risk was considered. This
assessment is a result of not showing the data of the group
treated only with the photosensitizer BF6 in the dark, although
the study indicated that there was a small reduction in the bac-
terial luminescence from mouse wounds.
No conflicts of interest were detected in any of the eleven
studies included in the review.
Results of the individual studies
Gram-negative bacteria
Pseudomonas aeruginosa is an opportunistic human pathogen
especially causing infections in chronic ulcers and burns. An
assay in a mouse model of wounds infected with a highly viru-
lent P. aeruginosa strain combined tricationic fullerene-
mediated aPDT with a suboptimal dose of tobramycin
(Table 2), reporting a synergistic therapeutic effect capable of
curing 60% of mice who would otherwise all die with this fatal
infection.22 These results were in agreement with those pre-
sented by Collins et al. in a study against biofilm-forming
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Table 2 Studies of combinations of in vivo aPDT plus other treatments used against bacterial infections, candidiasis, atypical Mycobacterium species and dermatophytes and mold infections of
the skin and mucosa
















groups/type Synergy Observed effect Bibliography
5 × 5 mm excisional
wound down to the
panniculus carnosus +
50 μl of a PBS
suspension containing
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aliquots into the
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groups/type Synergy Observed effect Bibliography
5 µl PBS inoculum
aliquots into the
hemocoel via the last
left proleg containing



































Ciclopirox olamine 0.65 mg per mice
topically every 48 h
over a period of 7
days













Patient S. schenckii Itraconazole Intermittent low
200 mg day−1, 7
days, 1 per month
doses





















on the right ankle
Patient F. monophora Terbinafine 250 mg day−1 oral 5-
ALA

















Patient F. monophora Terbinafine 250 mg day−1 oral 5-
ALA

















Chromoblastomycosis Patient A. alternata Itraconazole Short course of
itraconazole
(400 mg day−1 oral




LED 633 ± 10 80 2 Itraconazole
and subsequent
5-ALA-aPDT
Yes Clinical cure Liu and Xia
(2014)37
5-ALA: 5-aminolevulinic acid; aPDT: antimicrobial photodynamic therapy; BF6: BF6 fullerene; CFU: colony forming unit; ICG: indocyanine green; LED: light-emitting diode; MB: methylene blue; ND: no data; TBO:



































































































































P. aeruginosa: using the same antibiotic plus aPDT, although
based on another PS (meso-tetra (N-methyl-4-pyridyl) porphine
tetra tosylate), they observed greater inactivation and a
decrease in tobramycin MIC.23
Enterococcus faecium has emerged as one of the most impor-
tant pathogens in healthcare-associated infections worldwide
due to its intrinsic and acquired resistance to many anti-
biotics, including vancomycin.6,20 Enterococcus faecalis is an
opportunistic pathogen isolated from patients with different
types of infections including wounds and surgical-sites.20
Methylene blue(MB)-aPDT combined with antimicrobial
agents (ampicillin, streptomycin, gentamicin or vancomycin)
increased the sensitivity of bacteria to these antibiotics.20 The
survival of G. mellonella larvae infected with a vancomycin-
resistant Enterococcus (VRE) strain, was extended when vanco-
mycin was administered after aPDT (Table 2). However, when
vancomycin or aPDT was administered separately, no exten-
sion of caterpillar survival was observed. It is possible that the
permeabilization of the bacterial cell wall by the sub-lethal
aPDT makes it more susceptible to the antibiotic. The results
with E. faecium and E. faecalis were similar.
Atypical mycobacteria
Mycobacterial skin infections other than Mycobacterium tuber-
culosis and Mycobacterium leprae are a type of refractory infec-
tion typically treated with different combinations of various
antibiotics over 6–12 months.19
Mycobacterium fortuitum is highly resistant to primary anti-
tuberculosis drugs, and thus is very difficult to treat. A patient
with multiple skin abscesses caused by M. fortuitum was
treated with different antibiotics (clarithromycin, rifampin,
levofloxacin, and ethambutol hydrochloride) plus application
of a protocol of 5-aminolevulinic acid (5-ALA)-aPDT (Table 2).
The combination significantly shortened the treatment time
for the infection.24
The efficacy and safety of 5-ALA-PDT combined with
different antibiotics were tested in four patients diagnosed
with atypical mycobacterial skin infections caused by
M. fortuitum, Mycobacterium chelonae ssp abcessus,
Mycobacterium gordonae or Mycobacterium gilvum respectively.
The four patients were treated for a total of 3 months and dis-
played no signs of recurrence over 3 months of follow-up. Due
to the fact that each different atypical Mycobacterium species is
sensitive to different drugs, the combination of antibiotics
used to treat these infections was different in each case, but all
included clarithromycin and moxifloxacin hydrochloride19
(Table 2).
Yeasts
Candida albicans is the most prevalent pathogenic yeast. It
does not only cause skin infections, but also oral and genital
mucosal infections.25
Cai et al. presented a clinical case of a cutaneous granu-
loma caused by C. albicans treated with itraconazole for
1 month and two sessions of 5-ALA-aPDT (Table 2). The
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and the authors concluded that including aPDT in the treat-
ment was beneficial.26
Chibebe et al. confirmed that MB-aPDT prolonged the sur-
vival of G. mellonella larvae infected with C. albicans. A fluco-
nazole-resistant C. albicans strain was used to test the combi-
nation of MB-aPDT and fluconazole (Table 2). Administration
of fluconazole either before or after exposing the larvae to
aPDT significantly prolonged the survival of the caterpillars
compared to each treatment used alone.21 These results were
in agreement with those presented by Giroldo et al. and Lyon
et al. in vitro. The former demonstrated that both planktonic
suspensions and biofilms were much more susceptible to anti-
fungal drug treatments after MB-aPDT, which may be due to
an increase in membrane permeability by the aPDT.27 They
later evaluated in vitro the combination of MB-aPDT and fluco-
nazole against fluconazole-resistant C. albicans strains, and
reported a synergistic effect.28
Dermatophytes and non-dermatophyte fungi
Trichophyton rubrum is an anthropophilic fungus that colo-
nizes the upper layers of dead skin causing athlete’s foot, ony-
chomycosis and ringworm throughout the world.29
To our knowledge, the study from Baltazar et al. is the only
one that explores the combination of cyclopiroxolamine, a
hydroxypyridone antifungal drug, and toluidine blue O-aPDT
against T. rubrum in a murine model (Table 2). aPDT alone sig-
nificantly reduced the fungal burden by 87% compared with
the untreated group and it was 64% more efficient than cyclo-
piroxolamine alone, and both treatments together showed a
synergistic combination, reducing the damage caused by the
fungus in the skin. aPDT also reduced the myeloperoxidase
levels, but not the activity of N-acetylglucosaminidase,
suggesting that there was a reduction in neutrophils but not of
macrophages within the affected tissue. Furthermore, this
study correlated the effective production of ROS with PDT
efficacy.30
Sporothrix schenckii causes a subcutaneous mycosis known
as sporotrichosis. Infection generally occurs by traumatic
inoculation of soil, plants, and organic matter contaminated
with the fungus into the skin.31
Gilaberte et al. used intralesional 1% MB-aPDT in combi-
nation with intermittent low doses of itraconazole in a patient
with recalcitrant cutaneous sporotrichosis (Table 2). Complete
microbiological and clinical responses were obtained when
both treatments were combined, in contrast to the antifungal
treatment alone, which could not be fully administered to the
patient due to a pre-existing chronic liver disease. However,
MB-aPDT alone was not clinically tested, and it could be the
case that the entire effect was due to the aPDT alone. In fact
in vitro testing with the strain isolated from the patient showed
that whereas MAL-aPDT was not able to photoinactivate the
fungus, any of the phenothiazinium dyes tested (including
MB) produced more than 6 log10 reduction in the number of
CFU mL−1.32
Fonsecaea spp. is the main causative agent of chromoblasto-
mycosis, one of the most frequently encountered mycoses in
tropical and temperate regions, and which is associated with
low rates of cure and high relapse rates.33,34
There are two reports of refractory cases of this infection
successfully being treated with a combination of 5-ALA-PDT
plus terbinafine33 or 5-ALA-PDT plus itraconazole34 (Table 2).
The latter report was supported by an in vitro study that
showed growth inhibition of 5-ALA-aPDT against Fonsecaea
monophora. No response was obtained at first with terbinafine
(250 mg day−1 oral, 6 months) and itraconazole (200 mg day−1
oral, 1 month) alone or with these two antifungals in combi-
nation (2 periods of 1 month) and then 5-ALA-aPDT was added
(Table 2). As a result, the lesions improved but new lesions
developed after the cessation of PDT. Thereafter, positive clini-
cal improvement was obtained when voriconazole (200
mg day−1 oral) was combined with terbinafine (250 mg day−1 oral)
for 2 months.
The results obtained in these studies33,34 agree with pre-
vious reports35,36 that concluded that aPDT could be successfully
employed in combination with systemic antifungal drugs, and
which proposed itraconazole plus aPDT as the combination with
the greatest potential benefit in the treatment of F. monophora
infections although they did not specify a protocol.
Alternaria alternata is a rare etiologic agent of phaeohypho-
mycosis in immunocompromised patients, and which had
never been reported to cause chromoblastomycosis until the
clinical case presented by Liu and Xia. They described
A. alternata as the etiological agent of chromoblastomycosis
for the first time, and the patient was successfully treated with
a short course of itraconazole and subsequent 5-ALA-aPDT.
The usual management strategy consists of long courses of
antifungal chemotherapy, such as itraconazole or terbinafine
which is continued until there is clinical resolution, which is
usually after several months of therapy. When PDT with 20%
5-ALA cream incubated for 3 hours followed by irradiation was
tested, the lesions clinically improved after the first two ses-
sions37 (Table 2).
Risk of bias across studies
The small number of studies (N = 11) that make up our entire
group of analysis, the fact that most of them were clinical
cases with heterogeneous treatment protocols (N = 7) and
none were clinical trials, together constitute the main limit-
ations of our review. These limitations mean that the accumu-
lated evidence was reduced and not free from bias: the risk of
bias within studies has already been commented on section
Risk of bias within studies and we must add the risk of publi-
cation bias that we cannot quantify. Consequently, the risk of
bias for each given outcome across studies is high.
Summary of evidence and limitations
In general, the combination of aPTD plus antimicrobial
therapy has the potential to reduce treatment times, lower the
drug dosage, avoid drug toxicity, improve patient compliance,
and diminish the risk of developing resistance. Negative
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effects are not reported in any clinical case or animal study
analyzed. It seems that the best option is to administer the
antibiotic or the antifungal drug after aPDT rather than before,
although the specific mechanism of action is not completely
understood. The hypothesis is that aPDT damages the
microbial cell wall or membrane, which allows better pene-
tration of the drug. On the other hand, in those infections that
require a long course of antibiotics or antifungals, it seems
that the repetition of the aPDT could enhance the effect of the
antimicrobials (see Table 2). According to this review, there are
not enough evidence to establish the best protocol for aPDT
combined with antimicrobials for the different cutaneous and
mucosal infections. Therefore, the length of the antimicrobial
and the number of PDT sessions should be determined
depending on the clinical and microbiological response. More
clinical studies are needed in order to determine the optimal
combinations and the best treatment protocols supported by
existing evidence (Table 4).
Conclusions
aPTD combined with antimicrobial agents is promising for the
management of skin and mucous membrane infections
because:
(1) aPDT may increase the antimicrobial effect of antibiotics
and antifungals;
(2) The combination of aPDT with conventional antimicro-
bials can reduce the dose needed to achieve a bactericidal/fun-
gicidal effect;
(3) The combination may turn a microorganism that is
initially resistant to a specific antimicrobial drug into a micro-
organism that is sensitive to that drug;
(4) In some cases, the addition of aPDT can shorten the
antimicrobial treatment course.
The best option would be either to apply aPDT followed by
the antimicrobial compounds or to administer periodic ses-
sions of aPDT in long treatments with antimicrobials.
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